This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
14 Mar 2019

Bringing next generation single-use sensor technologies to the life science market

Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.

Pall Corporation has partnered with Broadley-James Corporation to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors. With applications across upstream and downstream unit operations, the sensor will be integrated into Pall Biotech’s single-use (SU) technologies, as well as other commercially available bioprocessing platforms.

“Pall’s single-use bioprocessing know-how and Broadley-James’ expertise in sensor development have proven complementary in addressing critical customer pain points in modern bioprocessing,” explained Martin Smith, Chief Technology Officer of Pall Corporation. “In particular, the new single-use pH sensor solution allows us to offer customers the robustness of traditional sensor technologies integrated into their single-use systems.”

The novel SU pH sensors leverage widely accepted glass electrochemical technology, the only method that meets international standards for pH measurement. The design includes a calibrated buffer storage environment for the sensor to eliminate previous constraints during pre-integration of glass pH sensors into consumables. Users will be able to operate in closed systems, without sacrificing performance.

“Customers currently rely on calibration data gathered before the sensor is sterilized, which can affect the measurement accuracy,” said Robert Garrahy, Vice-President at Broadley-James. “Our patent-pending new storage solutions design features a known pH buffer, enabling robust pre-use calibration. By pairing trusted technology with cutting-edge design, we are able to offer the best balance of risk reduction and performance.”

The Broadley-James single-use probe and flow cell pH sensors are currently in beta testing and when launched will be available exclusively through Pall Biotech. Parallel technical and process development support is also available to optimize use of this new technology.

Mentioned Companies
Pall Corporation Filltration & Separations (Thailand) Ltd.
View company profile

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.